To rule out an ADCC effect on the anti‐tumor activity, NK cells were pre‐incubated with anti‐CD16/CD32 mAb to block Fc‐receptor binding prior to the NK‐cell cytotoxicity assays and in vivo experiments. This evidence concerns the gene FCGR3A and neoplasm.